To access this element change to forms mode OFF
Grant Award View - GA89324
Sodium Selenate as a Disease Modifying Treatment for Progressive...
GA ID:
GA89324
Agency:
Department of Health and Aged Care
Approval Date:
25-May-2020
Publish Date:
29-Jun-2020
Category:
Health and Medical Research
Grant Term:
1-Jun-2020 to 31-May-2025
Value (AUD):
$2,639,490.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 19/20 1.1 Health Policy Research and Analysis
Grant Program:
2019_MRFF_RCRDUN_Neurological_Disorders_2020
Grant Activity:
Sodium Selenate as a Disease Modifying Treatment for Progressive Supranuclear Palsy (Sodium Selenate for PSP)
Purpose:
Progressive supranuclear palsy (PSP) is a fatal, neurodegenerative disease that affects people greater than40 years. Patients suffer progressive loss of balance, abnormal eye movements and reduced thinking ability, particularly planning, organisation and language. There is currently no cure or treatment that targets the underlying cause. This clinical trial will test the effectiveness of sodium selenate as a new treatment to slow or stop the progression of patients affected by this devastating disease.
GO ID:
GO Title:
MRFF Clinical Trials Activity - RCRDUN Initiative – 2019 Neurological Disorders Grant Opportunity
Internal Reference ID:
MRF1200254
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Monash University
Recipient ABN:
12 377 614 012
Grant Recipient Location
Suburb:
Clayton
Town/City:
Clayton
Postcode:
3800
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, SA, QLD
Postcode:
Multiple
Country:
AUSTRALIA